Johnson & Johnson (J&J) and the company’s subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability related to allegations that the drug maker promoted the prescription drugs Risperdal, Invega and Natrecor for unapproved uses, and provided kickbacks to physicians and the nation’s largest long-term care pharmacy provider.
U.S. Attorney General Eric Holder announced the deal on November 4. Holder said J&J improperly marketed Risperdal for treatment of psychotic symptoms in elderly, non-schizophrenic patients. The drug is approved by the U.S. Food and Drug Administration (FDA) only for individuals with schizophrenia. The attorney general also accused J&J of improperly marketing Risperdal and Invega for treatment of dementia. As a result, insurance companies paid for claims they should not have been paying for, according to CNN.com. More Johnson & Johnson Admits to Improperly Marketing Prescription Drugs for Unapproved Purposes